BofA raised the firm’s price target on Elevance Health (ELV) to $385 from $370 and keeps a Neutral rating on the shares, stating that its higher target reflects higher peer multiples.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Appoints Amy Schulman as Independent Director
- Cantor Fitzgerald says CMS guidance reinforces 2026 as ‘difficult for Medicaid’
- Republican lawmakers have yet to agree on healthcare plan, WSJ reports
- Trump Weekly: White House postpones healthcare proposal after backlash
- Elevance Health price target raised to $400 from $380 at TD Cowen